Japan Cancer Drug Market, Dosage, Price and Clinical Trials Insight 2025

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"Japan Cancer Drug Market, Dosage, Price and Clinical Trials Insight 2025" Report Highlights:

Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
Insight on Cancer Drugs In Clinical Trials: 360 Drugs
Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
Marketed Cancer Drug Clinical Insight by Companies and Indication: 141 Drugs
Cancer Drug Price, Dosage and Sales Insight: 250 Graphs
Cancer Clinical Pipeline By Company, Indication and Phase

Cancer drug market in Japan is witnessing positive growth outlook similar to patterns observed at global levels. The domestic and multinational companies operating in Japan have launched several innovative products in the market driving the overall sales levels in recent years. The increasing geriatric population, RandD spending for new drug innovation, availability of targeted drug therapies are the prominent factors leading to above average growth of cancer drugs market in Japan. The future market growth for cancer drugs and therapies is expected to be almost 70% in absolute terms by 2025 as compare to 2018 levels.

Targeted therapy has the leading share in the Japan cancer drug market while the immunotherapy is the second leading type of therapy. This is due to the ability of targeted therapies to kill only malignant cells thereby exhibiting better treatment outcomes. In addition, elevated efficacy and higher survival rates associated with the use of targeted therapy drugs are other reasons that fuel the growth of the market. In the case of immunotherapy, it is the fastest growing segment in Japan pharmaceutical market as it is widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body, which makes them less toxic as compared to other modes of cancer therapies. Hormonal therapy and chemotherapy are not commonly used in Japan as chemotherapy has several adverse effects and hormonal therapy is not able to treat all type of cancers.

In Japan, prostate and lung cancer therapeutics will lead the cancer drug market in upcoming years, which is mainly due to presence of huge geriatric population of Japan. Currently, about 28% of the total population of Japan belongs to the age more than 65 years and this share is expected to increase in upcoming years. Further, the breast cancer drug market will also emerge as the leading segment of Japan caner drug market in near future as the cases of breast cancer is increasing rapidly in Japan. The overall Cancer cases in Japan are also rising and hence the demand of anticancer drugs is expected to increase rapidly in future years.

Japanese government will play a prominent role in the rapid growth of cancer drug market by providing favorable policies framework for easy drug approval, production and marketing of products. A policy framework change is required in order to make drug approval process simpler so that the globally available products of leading MNCs can enter the Japanese market and are easily accessible to desired targeted population. In addition to this, it is also necessary to make the drug approval process faster so that the essential and highly effective drugs get approve on right time. As the leading regional companies of Japan is witnessing sales breakdown, the government of Japan can play a major role to encourage these companies for continuous production of the branded as well as generic anticancer drugs.

Several new drugs targeting different type of cancer are about to get approved by PMDA very soon, which will take this market segment to the next level. About 1617 cancer related clinical trials related to more than 350 cancer drugs are under investigation in Japan in which about 30% trials are in late development stage. The investments related to research and development is also increasing and many innovative cancer targeting therapies is expected to get approved in Japan, which will act as game changer in the treatment of cancer.

The future of Japanese cancer drug market seems to the sustain the past growth trends and will continue to its upward growth trajectory in coming years. Cancer drug market opportunity is expected to surpass US$ 15 Billion by 2025 driven by increasing number of clinical trials, availability of multiple products and the favorable steps undertaken by various stake holders of the pharmaceutical market. The Japan cancer drug market growth will take place at tremendous pace and this segment will emerge as an ocean of opportunities in near future.

1. Japan Cancer Drug Market Insight

1.1 Overview

1.2 Current Market Scenario

2. Japan - Cancer Prevalence and Statistics

2.1 Overview

2.2 By Cancer Type

2.2.1 Colorectum Cancer

2.2.2 Lung Cancer

2.2.3 Stomach Cancer

2.2.4 Prostate Cancer

2.2.5 Breast Cancer

2.3 By Gender and Age

3. Japan - Drug Approval and Regulation Landscape

3.1 Japan - Drug Regulatory Agencies

3.1.1 Ministry of Health, Labor and Welfare (MHLW)

3.1.2 Pharmaceuticals and Medical Devices Agency (PMDA)

3.2 Drug Approval Process

3.2.1 New Drug Approval (NDA) Application Process

3.2.2 Generic Drug approval Process

3.2.3 Orphan Drug Approval

4. Japan - Drug Pricing and Reimbursement Policies

4.1 Drug Pricing in Japan

4.1.1 Pricing of New Pharmaceuticals

4.1.2 Pricing of Generics and Biosimilars

4.2 Reimbursement Policies

5. Japan Cancer Drug Market - Clinical Insight

5.1 By Phase

5.2 By Status

5.3 By Cancer Type

5.3.1 Breast Cancer

5.3.2 Colorectal Cancer

5.3.3 Prostate Cancer

5.3.4 Lung Cancer

5.3.5 Stomach Cancer

6. Japan Breast Cancer Drug Market - Availability, Dosage and Price Analysis

6.1 HER2 inhibitors

6.1.1 Herceptin

6.1.2 Kadcyla

6.1.3 Perjeta (Pertuzumab)

6.1.4 Enhertu (Antibody Drug Conjugate)

6.1.5 Tykerb (Lapatinib)

6.2 Hormone Therapy

6.2.1 Letrozole

6.2.2 Anastrazole (Arimidex)

6.2.3 Megestrol

6.2.4 Faslodax (Fulvestrant)

6.2.5 Toremifene

6.2.6 Exemestane (Aromasin)

6.3 CDK 4/6 Inhibitors

6.3.1 Verzenio (Abemaciclib)

6.3.2 Ibrance

7. Japan Prostate Cancer Market – Availability, Dosage and Price Analysis

7.1 Patented Drugs

7.1.1 Xtandi (Enzalutamide)

7.1.2 Erleada (Apalutamide)

7.1.3 Nubeqa

7.1.4 Xofigo (Radium Ra 223 dichloride)

7.2 Generic Drugs

7.2.1 Abiraterone

7.2.2 Bicalutamide

7.2.3 Nilutamide

7.2.4 Flutamide

8. Japan Lung Cancer Drug Market – Availability, Dosage and Price Analysis

8.1 Patented Drugs

8.1.1 Alimta (Pemetrexed)

8.1.2 Alecensa (Alectinib)

8.1.3 Gilotrif

8.1.4 Lorbrena

8.1.5 Portrazza (Necitimumab)

8.1.6 Rozlytrek

8.1.7 Tagrisso

8.1.8 Vizimpro (Dacomitinib)

8.1.9 Xalkori (Crizotinib)

8.1.10 Zykadia (Certinib)

8.2 Generic Drugs

8.2.1 Vinorelbine

9. Japan Colorectum Cancer Drug Market – Availability, Dosage and Price Analysis

9.1 Patented drugs

9.1.1 Lonsurf

9.1.2 Vectibix (Panitumumab)

9.1.3 Zaltrap

9.2 Generic Drugs

9.2.1 Irinotecan

9.2.2 Oxaliplatin

10. Other Leading Cancer Drugs – Availability, Dosage, Price and Sales Analysis

10.1 Avastin (Bevacizumab)

10.2 Mabthera/Rituxan

10.3 Tecentriq

10.4 Opdivo

10.5 Revlimid

10.6 Keytruda

10.7 Imbruvica

11. Japan Cancer Biosimilar Market – Availability, Dosage and Price Analysis

11.1 Biosimilar of Avastin

11.2 Biosimilars of Herceptin

11.3 Rituxan’s Biosimilar

12. Japan Cancer Drugs Market Dynamics

12.1 Market Drivers

12.2 Challenges to Overcome

13. Japan Cancer Drug Market Future Outlook

14. Japan Cancer Clinical Pipeline By Company, Indication and Phase

14.1 Research

14.2 Preclinical

14.3 Clinical

14.4 Phase-I

14.5 Phase-I/II

14.6 Phase-II

14.7 Phase-II/III

14.8 Phase-III

14.9 Preregistration

14.10 Registered

15. Japan Marketed Cancer Drug Clinical Insight by Companies and Indication

16. Competitive Landscape

16.1 Regional Companies

16.1.1 Takeda Pharmaceuticals

16.1.2 Daiichi Sankyo

16.1.3 Kyowa Kirin

16.1.4 Mitsubishi Taneba Pharma Co.

16.1.5 Otsuka Pharmaceutical Co. Ltd.

16.1.6 Eisai Co. Ltd.

16.1.7 Astellas Pharma

16.2 Multinational Company

16.2.1 Novartis

16.2.2 Amgen

16.2.3 Eli Lilly

16.2.4 Merck

16.2.5 Pfizer

16.2.6 GlaxoSmithKline plc

16.2.7 Roche

16.2.8 Novartis

16.2.9 Amgen

16.2.10 Eli - Lilly

16.2.11 Merck

16.2.12 Pfizer

16.2.13 GlaxoSmithKline plc

16.2.14 Roche

Figure 1-1: Japan – Per Capita Healthcare Expenditure (US$/JPY), 2017 and 2018

Figure 1-2: Japan – Heath care Expenditure (US$/JPY Billion), 2017 and 2018

Figure 1-3: Japan – Per Capita Heath care Expenditure by Age (US$/JPY), 2018

Figure 1-4: Global - Pharmaceutical Market Size by Leading Countries (US$ Billion), 2018

Figure 1-5: Global - Pharmaceutical Market Size by Leading Countries (US$ Billion), 2018

Figure 1-6: Estimated Cancer Cases – Global v/s Japan (Million), 2020

Figure 1-7: Japan – Cancer Drug Market Size (US$ Billion), 2018 - 2025

Figure 1-8: Cancer Drug Market Size – Japan v/s Global (US$ Billion), 2019

Figure 1-9: Cancer Drug Market Size – Japan v/s Global (US$ Billion), 2019

Figure 1-10: Japan – Volume Share of Generics (%), 2011 , 2015, 2017 and 2020

Figure 2-1: Japan – Newly Diagnosed Cancer Cases, 2018, 2020 and 2025

Figure 2-2: Japan – Cancer Deaths Statistics, 2018, 2020 and 2025

Figure 2-3: Age Standardized Cancer Incidence Rate – Japan v/s Global Average (Per 100,000), 2018

Figure 2-4: Age Standardized Cancer Mortality Rate – Japan v/s Global Average (Per 100,000), 2018

Figure 2-5: Japan – Newly Diagnosed Cancer Cases by Type, 2018

Figure 2-6: Japan – Newly Diagnosed Cancer Cases by Type (%), 2018

Figure 2-7: Japan – Cancer Related Deaths by Type, 2018

Figure 2-8: Japan – Newly Diagnosed Colorectum Cancer Cases, 2018, 2020 and 2025

Figure 2-9: Japan – Newly Diagnosed Colorectum Cancer Cases by Type, 2018

Figure 2-10: Japan –Colorectum Cancer Related Deaths, 2018, 2020 and 2025

Figure 2-11: Japan – Age Standardized Colorectum Cancer Incidence and Mortality Rate (Per 100,000), 2018

Figure 2-12: Japan – Newly Diagnosed Lung Cancer Cases, 2018, 2020 and 2025

Figure 2-13: Japan –Lung Cancer Related Deaths, 2018, 2020 and 2025

Figure 2-14: Japan – Age Standardized Lung Cancer Incidence and Mortality Rate (Per 100,000), 2018

Figure 2-15: Japan – Newly Diagnosed Stomach Cancer Cases, 2018, 2020 and 2025

Figure 2-16: Japan – Stomach Cancer Related Deaths, 2018, 2020 and 2025

Figure 2-17: Japan – Age Standardized Stomach Cancer Incidence and Mortality Rate (Per 100,000), 2018

Figure 2-18: Japan – Newly Diagnosed Prostate Cancer Cases, 2018, 2020 and 2025

Figure 2-19: Japan – Prostate Cancer Related Deaths, 2018, 2020 and 2025

Figure 2-20: Japan – Age Standardized Prostate Cancer Incidence and Mortality Rate (Per 100,000), 2018

Figure 2-21: Japan – Newly Diagnosed Breast Cancer Cases, 2018, 2020 and 2025

Figure 2-22: Japan – Breast Cancer Related Deaths, 2018, 2020 and 2025

Figure 2-23: Japan – Age Standardized Breast Cancer Incidence and Mortality Rate (Per 100,000), 2018

Figure 2-24: Japan – Newly Diagnosed Cancer Cases by Gender, 2018

Figure 2-25: Japan – Cancer Deaths by Gender, 2018

Figure 2-26: Japan – Age Standardized Cancer Incidence Rate by Gender (Per 100,000), 2018

Figure 2-27: Japan – Age Standardized Cancer Mortality Rate by Gender (Per 100,000), 2018

Figure 2-28: Japan – Estimated Number of Newly Diagnosed Cancer Cases in Males, 2020 and 2025

Figure 2-29: Japan – Estimated Number of Newly Diagnosed Cancer Cases in Females, 2020 and 2025

Figure 2-30: Japan – Male Cancer Cases by Type, 2018

Figure 2-31: Japan – Male Cancer Cases by Type, 2018

Figure 2-32: Japan – Male Cancer Cases by Type, 2018

Figure 2-33: Japan – Female Cancer Cases by Type, 2018

Figure 2-34: Japan – Female Cancer Cases by Type (%), 2018

Figure 2-35: Japan – Female Cancer Cases by Type, 2018

Figure 2-36: Japan – Newly Diagnosed Cancer Cases by Age, 2018

Figure 2-37: Japan – Newly Diagnosed Cancer Cases by Age (%), 2018

Figure 2-38: Japan – Newly Diagnosed Cancer Cases by Age, 2018

Figure 2-39: Japan – Newly Diagnosed Cancer Cases by Age (%), 2018

Figure 3-1: Japan – PMDA Review Process for Drugs and Medical Devices

Figure 3-2: Japan - PMDA Regulatory System for Practical Application of Cellular and Tissue Based Product

Figure 3-3: Japan - Organisation of PMDA

Figure 3-4: Japan – New Drug Marketing Approval Process

Figure 4-1: Outline of Pricing New Pharmaceuticals

Figure 4-2: Japan - Premium Applied During Price Fixation of New Pharmaceuticals

Figure 4-3: Japan - Components of Cost Calculation Method

Figure 4-4: Japan - Price of New Generic and Oral Generic with more than 10 Brands v/s Original Product (%), April’2020

Figure 4-5: Japan – Price of Biotechnological and Chemically derived Biosimilars v/s Original Products

Figure 4-6: Japan: Price Reduction of Branded Drugs by Generic Replacement Rate (%)

Figure 5-1: Japan – Number of Clinical Trial related to Cancer v/s Total, April’2020

Figure 5-2: Japan – Number of Clinical Trial related to Cancer v/s Total (%), April’2020

Figure 5-3: Japan – Number of Clinical Trial by Phase, April’2020

Figure 5-4: Japan – Number of Clinical Trials by Phase (%), April’2020

Figure 5-5: Japan – Number of Drug In Clinical Trials by Phase, 2020 till 2025

Figure 5-6: Japan – Number of Drug In Clinical Trials by Phase, 2020 till 2025

Figure 5-7: Japan – Number of Clinical Trial by Status, April’2020

Figure 5-8: Japan – Number of Breast Cancer Clinical Trial by Phase, April’2020

Figure 5-9: Japan – Number of Breast Cancer Clinical Trial by Phase (%), April’2020

Figure 5-10: Japan – Number of Breast Cancer Clinical Trial by Status, April’2020

Figure 5-11: Japan – Number of Colorectum Cancer Clinical Trial by Phase, April’2020

Figure 5-12: Japan – Number of Colorectum Cancer Clinical Trial by Phase (%), April’2020

Figure 5-13: Japan – Number of Colorectum Cancer Clinical Trial by Status, April’2020

Figure 5-14: Japan – Number of Prostate Cancer Clinical Trial by Phase, April’2020

Figure 5-15: Japan – Number of Colorectum Cancer Clinical Trial by Phase (%), April’2020

Figure 5-16: Japan – Number of Prostate Cancer Clinical Trial by Status, April’2020

Figure 5-17: Japan – Number of Lung Cancer Clinical Trial by Phase, April’2020

Figure 5-18: Japan – Number of Lung Cancer Clinical Trial by Phase (%), April’2020

Figure 5-19: Japan – Number of Lung Cancer Clinical Trial by Status, April’2020

Figure 5-20: Japan – Number of Stomach Cancer Clinical Trial by Phase, April’2020

Figure 5-21: Japan – Number of Lung Cancer Clinical Trial by Phase (%), April’2020

Figure 5-22: Japan – Number of Lung Cancer Clinical Trial by Status, April’2020

Figure 6-1: Breast Cancer Drug Market Size – Global v/s Japan (US$ Billion), 2019

Figure 6-2: Breast Cancer Drug Market Size – Global v/s Japan (%), 2019

Figure 6-3: Herceptin – Approval Year by Cancer Type

Figure 6-4: Herceptin – FDA approval and PMDA Approval Year

Figure 6-5: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$/JPY), June’2020

Figure 6-6: Herceptin – Initial and Maintenance Dose for Breast Cancer Treatment (mg/kg), June’2020

Figure 6-7: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Breast Cancer (US$/JPY), June’2020

Figure 6-8: Herceptin – Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg), January’2020

Figure 6-9: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$/JPY), January’2020

Figure 6-10: Japan – Herceptin Annual Sales Value (US$/JPY Million), 2017 - 2019

Figure 6-11: Japan – Herceptin Quarterly Sales Value (US$/JPY Million), 2019

Figure 6-12: Japan – Herceptin Quarterly Sales Value (US$/JPY Million), 2019

Figure 6-13: Kadcyla – FDA Approval Year for Late Stage and Early Stage HER2+ Breast Cancer

Figure 6-14; Kadcyla – Price for Single Unit of 100mg and 150mg Intravenous Powder for Injection (US$), June’2020

Figure 6-15: Kadcyla - Duration of Single Treatment Cycle and Full Treatment of Early Stage HER2+ Breast Cancer (Weeks), June’2020

Figure 6-16: Kadcyla – Average Cost of Single Treatment Cycle and Full Treatment of Early Stage HER2 Breast Cancer (US$/JPY), June’2020

Figure 6-17: Kadcyla – Recommended Dose After 1st and 2nd Dose Reduction (mg/m2), June’2020

Figure 6-18: Perjeta – FDA and PMDA Approval Year

Figure 6-19: Perjeta – Patent Expiration Year by Region

Figure 6-20: Perjeta – Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$/JPY), June’2020

Figure 6-21: Perjeta – Initial and Maintenance Dose for Breast Cancer Treatment (mg/ 3 weeks), June’2020

Figure 6-22: Perjeta – Minimum and Maximum Treatment Cost for Breast Cancer (US$/JPY), June’2020

Figure 6-23: Perjeta – Minimum and Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$/JPY), January’2020

Figure 6-24: Japan – Perjeta Annual Sales Value (US$/JPY Million), 2017 - 2019

Figure 6-25: Japan – Perjeta Quarterly Sales Value (US$/JPY Million), 2019

Figure 6-26: Japan – Perjeta Quarterly Sales Value (US$/JPY Million), 2019

Figure 6-27: Enhertu – FDA and PMDA Approval Year

Figure 6-28: Enhertu – Disease Control, Tumor Shrinkage and Disease Elimination Rate (%)

Figure 6-29: Enhertu – Average Cost of Single Treatment Cycle and Annual Treatment Cost of Breast Cancer (US$/JPY), June’2020

Figure 6-30: Enhertu – Recommended Dose and Dose after Reduction (mg/Kg), June’2020

Figure 6-31: Tykerb – FDA and Japan Approval Year

Figure 6-32: Tykerb – Patent Issue and Expiration Year

Figure 6-33: Tykerb – Price for 150 Tablet Supply and Price per Unit of Oral Tablet (JPY/US$), April’2020

Figure 6-34: Tykerb – for HER2+ and HER2+ Metastatic Breast Cancer (mg per day), April’2020

Figure 6-35: Tykerb – Treatment and Rest Phase in Single Treatment Cycle (Days)

Figure 6-36: Letrozole – FDA and PMDA Approval Year

Figure 6-37: Letrozole – Price for a Supply of 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 6-38: Letrozole – Price for a Supply of 50 Tablets and Price per Unit Tablet (US$), June’2020

Figure 6-39: Letrozole – Price for a Supply of 90 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 6-40: Letrozole – Price for a Supply of 1000 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 6-41: Femara – Price for a Supply of 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 6-42: Letrozole – Daily, Monthly and Annual Treatment Cost using Branded and Generic Letrozole (US$), June’2020

Figure 6-43: Anastarzole - FDA and Generic Approval Year

Figure 6-44: Anastrazole - Price for Various Supplies of 1mg Tablet (US$/JPY), June’2020

Figure 6-45: Arimidex – Price for 30 Tablet Supply and Price Per Unit Tablet (US$/JPY), June’2020

Figure 6-46: Anastrazole – Daily, Monthly and Annual Treatment Cost for Breast Cancer (US$), 2020’January

Figure 6-47: Armidex – Daily, Monthly and Annual Treatment Cost for Breast Cancer (US$), 2020’January

Figure 6-48: Megastrol - FDA and Generic Approval Year

Figure 6-49: Megastrol – Price for Various Supplies of 40mg/ml Oral Suspension (US$/JPY), June’2020

Figure 6-50: Megastrol - Price for Supply of 150 ml and Price per ml of 625mg/5ml Oral Suspension (US$/JPY), June’2020

Figure 6-51: Megace ES - Price for Supply of 150 ml and Price per ml of 625mg/5ml Oral Suspension (US$/JPY), June’2020

Figure 6-52: Megastrol - Price for Supply of 100 Tablets and Price per Unit of 20mg Tablet (US$/JPY), June’2020

Figure 6-53: Megastrol - Price for Supply of 100, 250 and 500 Tablets of 40mg (US$/JPY), June’2020

Figure 6-54: Megestrol - Average Cost of Daily, Monthly and Annual Treatment using 40mg/ml Oral Suspension (US$), June’2020

Figure 6-55: Megestrol - Average Cost of Daily, Monthly and Annual Treatment using 40mg Oral Tablet (US$), June’2020

Figure 6-56: Fulvestrant - FDA and PMDA Approval Year

Figure 6-57: Fulvestrant – Average Price for a Supply of 10ml, 5ml and Price per ml of Intramuscular Solution (US$/JPY), June’2020

Figure 6-58: Faslodex – Average Price for a Supply of 10ml, 5ml and Price per ml of Intramuscular Solution (US$/JPY), June’2020

Figure 6-59: Fulvestrant – Number of Dose Administration in Initial and Subsequent Months, January’2020

Figure 6-60: Fulvestrant – Treatment Cost of Initial and Subsequent Months (US$), January’2020

Figure 6-61: Fulvestrant – Treatment Cost of Initial and Subsequent Year (US$), January’2020

Figure 6-62: Faslodex – Treatment Cost of Initial and Subsequent Months (US$), January’2020

Figure 6-63: Faslodex – Treatment Cost of Initial and Subsequent Year (US$), January’2020

Figure 6-64: Toremifene - FDA and First Generic Approval Year

Figure 6-65: Toremifene – Price for 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 6-66: Fareston – Price for 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 6-67: Toremifene - Average Cost of Daily, Monthly and Annual Treatment of Breast Cancer (US$), 2020’January

Figure 6-68: Fareston - Average Cost of Daily, Monthly and Annual Treatment of Breast Cancer (US$), 2020’January

Figure 6-69: Exemestane - FDA and First Generic Approval Year

Figure 6-70: Exemestane – Price for 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 6-71: Aromasin – Price for 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 6-72: Exemestane - Average Cost of Daily, Monthly and Annual Treatment of Breast Cancer (US$), 2020’January

Figure 6-73: Aromasin - Average Cost of Daily, Monthly and Annual Treatment of Breast Cancer (US$), 2020’January

Figure 6-74: Verzenio – FDA and PMDA Approval Year

Figure 6-75: Verzenio – Patent Issue and Expiration Year

Figure 6-76: Verzenio - Price for a Supply of 14 Tablets and Price per unit of Tablet (US$/JPY), June’2020

Figure 6-77: Verzenio - Recommanded Dose Modification for Adverse Effects in Monotherapy (mg)

Figure 6-78: Verzenio - Recommanded Dose Modification for Adverse Effects in Combinational Therapy (mg)

Figure 6-79: Ibrance – FDA and PMDA Approval Year

Figure 6-80: Ibrance - Year of Assigning and Expiration of Different Patents

Figure 6-81: Ibrance – Price for a Supply of 21 Capsules and Per Unit Cost of Ibrance Capsules (US$/JPY), June’2020

Figure 6-82: Ibrance – Treatment Cycle of Ibrance using 1 Capsule/Day (Days)

Figure 6-83: Ibrance – Recommanded Dose Modification for Adverse effects (mg)

Figure 7-1: Xtandi – FDA and Japan Approval Year

Figure 7-2: Xtandi – Patent Issue and expiration Year

Figure 7-3: Xtandi – Price for 120 Tablet Supply and Price per Unit of Oral Tablet (JPY/US$), April’2020

Figure 7-4: Xtandi – Recommended and Reduced Dose for Prostate Cancer Treatment (mg per day), April’2020

Figure 7-5: Xtandi – Cost of Single Capsule and Daily Treatment Cost (JPY/US$), April’2020

Figure 7-6: Erleada – FDA and Japan Approval Year

Figure 7-7: Erleada – Aragon related Patent Issue and expiration Year

Figure 7-8: Erleada – University of California related Patent Issue and expiration Year

Figure 7-9: Erleada – Price for 120 Tablet Supply and Price per Unit of Oral Tablet (JPY/US$), April’2020

Figure 7-10: Erleada – Recommended and Reduced Dose for Prostate Cancer Treatment (mg per day), April’2020

Figure 7-11: Nubeqa – FDA and Japan Approval Year

Figure 7-12: Nubeqa – Aragon related Patent Issue and Expiration Year

Figure 7-13: Nubeqa – Price for 120 Tablet Supply and Price per Unit of Oral Tablet (JPY/US$), April’2020

Figure 7-14: Nubeqa – Price of Single Tablet and Daily Treatment Cost (JPY/US$), April’2020

Figure 7-15: Xofigo – FDA and Japan Approval Year

Figure 7-16: Xofigo – Patent Issue and expiration Year

Figure 7-17: Xofigo – Duration of One Treatment Cycle and Full Treatment Duration for Prostate Cancer (Weeks), April’2020

Figure 7-18: Abiraterone - FDA and PMDA Approval Year

Figure 7-19: Aberaterone – Price of 30 Tablets and Price per unit of 250mg Tablet (US$/JPY), June’2020

Figure 7-20: Aberaterone – Price of 120 Tablets and Price per Unit of 250mg Tablet (US$/JPY), June’2020

Figure 7-21: Zytiga – Price of 120 Tablets and Price per unit of 250mg Tablet (US$/JPY), June’2020

Figure 7-22: Zytiga – Price of 60 Tablets and Price per Unit of 500mg Tablet (US$/JPY), June’2020

Figure 7-23: Abiraterone – Treatment Cost Comparision of Metastatic High-risk CSPC Using Branded and Generic Tablet (US$), January’2020

Figure 7-24: Abiraterone – Treatment Cost Comparision of Metastatic CSPC Using Branded and Generic Tablet (US$), January’2020

Figure 7-25: Bicalutamide - FDA and First Generic Approval Year

Figure 7-26: Bicalutamide - Price for 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 7-27: Casodex - Price for 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 7-28: Bicalutamide – Price of 100 Tablets and Price per Unit of 50mg Tablet (US$/JPY), June’2020

Figure 7-29: Bicalutamide – Price of 500 Tablets and Price per Unit of 50mg Tablet (US$/JPY), June’2020

Figure 7-30: Bicalutamide – Treatment Cost Comparision of Prostate Cancer Using Branded and Generic Tablet (US$), January’2020

Figure 7-31: Nilutamide - FDA and First Generic Approval Year

Figure 7-32: Nilutamide - Price for 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 7-33: Nilandron - Price for 30 Tablets and Price per Unit Tablet (US$/JPY), June’2020

Figure 7-34: Nilutamide – Initial and Maintenance Dose for Prostate Cancer Treatment (mg/day)

Figure 7-35: Nilutamide – Comparision of Initial Month Treatment Cost of Prostate Cancer Using Branded and Generic Tablet (US$), June’2020

Figure 7-36: Nilutamide – Comparision of Maintenence Month Treatment Cost of Prostate Cancer Using Branded and Generic Tablet (US$), June’2020

Figure 7-37: Flutamide - FDA and First Generic Approval Year

Figure 7-38: Flutamide - Price for 180 Capsules and Price per Unit Capsule (US$/JPY), June’2020

Figure 7-39: Eulexin - Price for 180 Capsules and Price per Unit Capsule (US$/JPY), June’2020

Figure 7-40: Flutamide – Comparision of Daily, Monthly and Annual Treatment of Prostate Cancer Using Branded and Generic Capsule (US$), January’2020

Figure 8-1: Alimta – FDA and Japan Approval Year

Figure 8-2: Alimta – Patent Issue and expiration Year

Figure 8-3: Alimta – Price for 120 Tablet Supply and Price per Unit of Oral Tablet (JPY/US$), April’2020

Figure 8-4: Alimta – Number of Treatment Cycle Required in Combination with Pembtrolizumab and Cisplatin , April’2020

Figure 8-5: Alecensa – FDA and Japan Approval Year

Figure 8-6: Alecensa - Patent Issue and expiration Year

Figure 8-7: Alecensa – Price for 240 Tablet Supply and Price per Unit of Oral Tablet (JPY/US$), April’2020

Figure 8-8: Alecensa - Recommended and Reduced Dose for NSCLC Treatment (mg per day), April’2020

Figure 8-9: Gilotrif – FDA and Japan Approval Year

Figure 8-10: Gilotrif - Patent Issue and expiration Year

Figure 8-11: Gilotrif – Price for 30 Tablet Supply and Price per Unit of Oral Tablet (JPY/US$), April’2020

Figure 8-12: Gilotrif - Recommended and Reduced Dose for NSCLC Treatment (mg per day), April’2020

Figure 8-13: Iressa – FDA and Japan Approval Year

Figure 8-14: Iressa – Price for 30 Tablet Supply and Price per Unit of Oral Tablet (JPY/US$), April’2020

Figure 8-15: Lorbrena – FDA Approval, Japan Approval and Patent expiration Years

Figure 8-16: Lorbrena - Price for 30 Tablet Supply and Price per unit of 25mg Oral Tablet (JPY/US$), April’2020

Figure 8-17: Lorbrena - Price for 30 Tablet Supply and Price per unit of 100 mg Oral Tablet (JPY/US$), April’2020

Figure 8-18: Lorbrena - Recommended and Reduced Dose for NSCLC Treatment (mg per day), April’2020

Figure 8-19: Portrazza - FDA and Japan Approval Year

Figure 8-20: Portrazza - Price for 50 ml Supply and Price per Unit of Intravenous Solution (JPY/US$), April’2020

Figure 8-21: Portrazza – Cost of Single Treatment Cycle and Annual Treatment Cost of NSCLC (JPY/US$), April’2020

Figure 8-22: Rozlytrek - FDA Approval, Japan Approval and Patent Expiration Year

Figure 8-23: Rozyltrek - Price for 30 Capsules Supply and Price per Unit of 100 mg Oral Tablet (JPY/US$), April’2020

Figure 8-24: Rozyltrek - Price for 90 Capsules Supply and Price per unit of 200 mg Oral Tablet (JPY/US$), April’2020

Figure 8-25: Rozyltrek – Pediatric Dose by Surface Area (mg), April’2020

Figure 8-26: Tagrisso - FDA and Japan Approval Year

Figure 8-27: Tagrisso - Patent Issue and Expiration Year

Figure 8-28: Tagrisso - Price for 30 Tablet Supply and Price per Unit of 200 mg Oral Tablet (JPY/US$), April’2020

Figure 8-29: Tagrisso - Recommended and Reduced Dose for NSCLC Treatment (mg per day), April’2020

Figure 8-30: Vizimpro - FDA and Japan Approval Year

Figure 8-31: Vizimpro - Patent Issue and Expiration Year

Figure 8-32: Vizimpro - Price for 30 Tablet Supply and Price per Unit of 200 mg Oral Tablet (JPY/US$), April’2020

Figure 8-33: Vizimpro - Recommended and Reduced Dose for NSCLC Treatment (mg per day), April’2020

Figure 8-34: Xalkori - FDA and Japan Approval Year

Figure 8-35: Xalkori - Patent Issue and Expiration Year

Figure 8-36: Xalkori - Price for 60 Capsule Supply and Price per Unit of Oral Capsule (JPY/US$), April’2020

Figure 8-37: Zykadia - FDA and Japan Approval Year

Figure 8-38: Zykadia - Patent Expiration Year by Assignee

Figure 8-39: Zykadia - Price for 84 Capsules Supply and Price per Unit of Oral Capsule (JPY/US$), April’2020

Figure 8-40: Zykadia - Recommended and Reduced Dose for NSCLC Treatment (mg per day), April’2020

Figure 8-41: Vinorelbine - FDA and First Generic Approval Year

Figure 8-42: Vinorelbine - Price for 5ml Supply and Price per ml of Intravenous Solution (US$/JPY), June’2020

Figure 8-43: Vinorelbine - Price for 5ml Supply and Price per ml of Intravenous Solution (US$/JPY), June’2020

Figure 8-44: Vinorelbine Monotherapy – Comparision of Treatment Cost of NSCLC Using Branded and Generic Intravenous Solution (US$), January’2020

Figure 8-45: Vinorelbine – Combinational Dose with 100mg/m2 and 120 mg/m2 Cisplatin (mg/m2), January’2020

Figure 9-1: Lonsurf – FDA Approval, Japan Approval and Patent Expiration Year

Figure 9-2: Lonsurf - Price for Various Supplies of 6.14 mg-15 mg Tablet (JPY/US$), April’2020

Figure 9-3: Lonsurf - Price for Various Supplies of 8.19mg-20mg Tablet (JPY/US$), April’2020

Figure 9-4: Lonsurf - Recommended Dose by Surface Area (mg per day)

Figure 9-5: Vectibix – FDA and Japan Approval Year

Figure 9-6: Vectibix - Price for 5 ml Supply and Price per Unit of Intravenous Solution (JPY/US$), April’2020

Figure 9-7: Vectibix - Price for 20 ml Supply and Price per Unit of Intravenous Solution (JPY/US$), April’2020

Figure 9-8: Zaltrap - FDA and Japan Approval Year

Figure 9-9: Zaltrap - Price for 4 ml Supply and Price per Unit of Intravenous Solution (JPY/US$), April’2020

Figure 9-10: Zaltrap - Price for 8ml Supply and Price per Unit of Intravenous Solution (JPY/US$), April’2020

Figure 9-11: Irinotecan - FDA and First Generic Approval Year

Figure 9-12: Irinotecan – Price for Various Supplies of Intravenous Solution (US$/JPY), June’2020

Figure 9-13: Camptosar – Price for Various Supplies of Intravenous Solution (US$/JPY), June’2020

Figure 9-14: Irinotecan – Minimum and Maximum Duration of Treatment Cycle (Weeks), January ’2020

Figure 9-15: Oxaliplatin - FDA and PMDA Approval Year

Figure 9-16: Oxaliplatin – Price of 50 mg and 100 mg Intravenous Powder for Injection (US$/JPY), June’2020

Figure 9-17: Oxaliplatin – Price of 10ml and 1ml Intravenous Solution for Injection (US$/JPY), June’2020

Figure 9-18: Eloxatin – Price of 10ml and 1ml Intravenous Solution for Injection (US$/JPY), June’2020

Figure 9-19: Eloxatin – Price of 20ml and 1ml Intravenous Solution for Injection (US$/JPY), June’2020

Figure 9-20: Oxaplatin – Duration of Single Treatment Cycle and Full Treatment of Stage III Colon Cancer (Weeks), 2020’January

Figure 10-1: Avastin – FDA and PMDA Approval Year

Figure 10-2: Avastin – Price for a Supply of 10 and Price for Single 4ml Solution for Injection (US$/JPY), June’2020

Figure 10-3: Avastin – Price for a Supply of 10 and Price for Single 16ml Solution for Injection (US$/JPY), June’2020

Figure 10-4: Avastin – Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC and Metastatic Cervical Cancer (US$/JPY), June’2020

Figure 10-5: Avastin – Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$/JPY), June’2020

Figure 10-6: Avastin – Duration of Treatment of Recurrent Glioblastoma and Renal Cell Carcinoma as Combinational and Monotherapy (Weeks), June’2020

Figure 10-7: Avastin – Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$/JPY), June’2020

Figure 10-8: Japan – Avastin Annual Sales Value (US$/JPY Million), 2017 - 2019

Figure 10-9: Japan – Avastin Quarterly Sales Value (US$/JPY Million), 2019

Figure 10-10: Japan – Avastin Quarterly Sales Value (US$/JPY Million), 2019

Figure 10-11: Gazyva – FDA Approval Year by Indication

Figure 10-12: Rituxan - FDA and Japan Approval Year

Figure 10-13: Rituxan – Price for a Supply of 10 ml and Price per ml of Solution for Injection (US$/JPY), June’2020

Figure 10-14: Rituxan – Price for a Supply of 50 ml and Price per ml of Solution for Injection (US$/JPY), June’2020

Figure 10-15: Rituxan – Price for a Supply of 100 ml and Price per ml of Solution for Injection (US$/JPY), June’2020

Figure 10-16: Rituxan – Average Cost of Initial and Subsequent Treatment Cycle for CLL Treatment (US$/JPY), June’2020

Figure 10-17: Rituxan – Duration of Single Treatment Cycle and Full Treatment of CLL (Weeks), June’2020

Figure 10-18: Japan – Rituxan Annual Sales Value (US$/JPY Million), 2017 - 2019

Figure 10-19: Japan – Rituxan Quarterly Sales Value (US$/JPY Million), 2019

Figure 10-20: Japan – Rituxan Quarterly Sales Value (US$/JPY Million), 2019

Figure 10-21: Tecentriq - FDA and Japan Approval Year

Figure 10-22: Tecentriq - Price for 14ml Supply and Price per ml of 840mg/14ml Intravenous Injection (US$/JPY), June’2020

Figure 10-23: Tecentriq - Price for 20ml Supply and Price per ml of 1200mg/20ml Intravenous Injection (US$/JPY), June’2020

Figure 10-24: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/m2 Week Dose (US$/JPY), June’2020

Figure 10-25: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$/JPY), June’2020

Figure 10-26: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$/JPY), June’2020

Figure 10-27: Japan – Tecentriq Annual Sales Value (US$/JPY Million), 2017 - 2019

Figure 10-28: Japan – Tecentriq Quarterly Sales Value (US$/JPY Million), 2019

Figure 10-29: Japan – Tecentriq Quarterly Sales Value (US$/JPY Million), 2019

Figure 10-30: Opdivo - FDA and Japan Approval Year

Figure 10-31: Opdivo - Patent Expiration Year by Region

Figure 10-32: Opdivo - Price for 4ml Supply and Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June’2020

Figure 10-33: Opdivo - Price for 10 ml Supply and Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June’2020

Figure 10-34: Opdivo - Price for 20 ml Supply and Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June’2020

Figure 10-35: Opdivo Monotherapy Therapy - Single Treatment Cycle and Full Treatment Average Cost (US$/JPY), June’2020

Figure 10-36: Opdivo Combination – Dose for Management of Melanoma and Renal Cell Carcinoma (mg/3 Weeks)), June’2020

Figure 10-37: Revlimid - FDA and Japan Approval Year

Figure 10-38: Revlimid – FDA Approval Year by Indication

Figure 10-39: Revlimid – FDA Approval and Patent Expiration Year

Figure 10-40: Revlimid – Price for 28 capsules and 100 Capsules of 2.5mg, 5mg and 10mg Capsules (US$/JPY), June’2020

Figure 10-41: Revlimid – Price for 21 capsules and 100 Capsules of 15mg, 20mg and 25mg Capsules (US$/JPY), June’2020

Figure 10-42: Revlimid – Recommended Daily Dose by Indications (mg)

Figure 10-43: Keytruda - FDA and Japan Approval Year

Figure 10-44: Keytruda – Patent Expiration Year by Region

Figure 10-45: Keytruda – Price for 4ml and 8ml Supply and Price per ml of Intravenous Injection (US$/JPY), June’2020

Figure 10-46: Keytruda – Duration of Single Treatment Cycle and Full Treatment of Melanoma and Other Cancers (Weeks), June’2020

Figure 10-47: Keytruda – Cost of Single and Full Treatment using Powder of Injection (US$/JPY), June’2020

Figure 10-48: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$/JPY), June’2020

Figure 10-49: Ibrutinib – FDA Approval Year by Indication

Figure 10-50: Ibrutinib – FDA Approval Year by Dosage Form

Figure 10-51: Imbruvica - FDA and Japan Approval Year

Figure 10-52: Imbruvica – Price for 90 and 120 Capsule Supplies of 140mg (US$/JPY), June’2020

Figure 10-53: Imbruvica Capsule – Price for 28 Capsule and Price per Unit Capsule of 70mg (US$/JPY), June’2020

Figure 10-54: Imbruvica Tablet – Price for 28 Tablets and Price per Unit Tablet of Various Doses (US$/JPY), June’2020

Figure 10-55: Imbruvica – Recommended Daily Dose by Indication (mg), May’2020

Figure 11-1: Avastin’s Biosimilar - FDA Approval Year

Figure 11-2: Mvasi - Price for 4ml Supply and Price per Unit of Intravenous Solution (JPY/US$), April’2020

Figure 11-3: Mvasi - Price for 16 ml Supply and Price per Unit of Intravenous Solution (JPY/US$), April’2020

Figure 11-4: Zirabev - Price for 4ml Supply and Price per Unit of Intravenous Solution (JPY/US$), April’2020

Figure 11-5: Zirabev - Price for 16 ml Supply and Price per Unit of Intravenous Solution (JPY/US$), April’2020

Figure 11-6: Japan - Avastin’s Biosimilar PMDA Approval Year

Figure 11-7: Herceptin’s Biosimilar - FDA Approval Year

Figure 11-8: Japan - Herceptin’s Biosimilar PMDA Approval Year

Figure 11-9: Kanjati: Price for 150 mg and 420 mg Supply of Intravenous Powder for Injection (JPY/US$), April’2020

Figure 11-10: Trazimera: Price for a supply of 150 mg and 420mg Intravenous Powder of (JPY/US$), April’2020

Figure 11-11: Rituxan Biosimilar - FDA Approval Year

Figure 11-12: Japan - Rituxan Biosimilar PMDA Approval Year

Figure 11-13: Ruxience - Price for a supply of 10 ml and Price per ml of Intravenous Solution (JPY/US$), April’2020

Figure 11-14: Ruxience - Price for a supply of 10 ml and Price per ml of Intravenous Solution (JPY/US$), April’2020

Figure 12-1: Japan Cancer Drug Market Drivers

Figure 12-2: Challenges for Japan Cancer Drugs Market

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request